Mubadala Cap­i­tal-backed on­col­o­gy biotech adds more cash to Se­ries A; Opti­nose shares pooled da­ta on nasal spray

Look­ing for a new way to re­de­fine pre­ci­sion on­col­o­gy by us­ing pa­tient tu­mor tis­sue grown in a petri dish, a North Car­oli­na biotech backed by blue-chip in­vestors is adding more to its cof­fers.

Backed by sov­er­eign wealth fund Mubadala Cap­i­tal, Xilis put out word Wednes­day that it added $19 mil­lion more to its Se­ries A round, orig­i­nal­ly worth $70 mil­lion and an­nounced back in 2021. So far, the funds will be used to ad­vance its plat­form — which es­sen­tial­ly en­tails that by tak­ing a piece of tu­mor tis­sue from a pa­tient and grow­ing it in a petri dish, founder and CEO Xil­ing Shen told End­points News last year that re­searchers can test thou­sands of ther­a­pies or drug com­bi­na­tions to see how the tu­mor might re­act.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER